Canada Markets closed

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
37.66-1.79 (-4.54%)
At close: 04:00PM EST
37.86 +0.20 (+0.53%)
After hours: 07:42PM EST
Sign in to post a message.
  • C
    Christian
    After these interviews, it is just a matter of time sava sp will go up again after cp rejected... where it belongs...
  • p
    paul
    That was a slam dunk interview ! Not invested in cassava, give it a high % chance of approval and some fantastic accounts of real life stories, he would also enter his own family members into SAVA trials, and wow the SEC had contacted him. He was awesome !
  • p
    paul
    Joe Springer TODAY 10 am interview with Dr Boris Nikolov don’t miss it !! He ran one of the simufilum phase 2 trials and is NOW running a phase 3 trial.. this is going to be fantastic!!! Tune in and like LONGS
  • s
    spinach_inquistion
    Got a call from my broker. Would I be interested in loaning some shares at a nice return, can sell anytime I want, yada yada yada. I thanked him and hung up. Transferred another 2000 to my account to buy more shares. The pool is shrinking and the ones on the inflatable rafts are looking to keep afloat. I suspect they know they will not make good on their short shares but will declare bankruptcy and leave someone else holding their obligations. I feel the end is getting close.
  • s
    scott
    I bought another 1000
  • p
    paul
    That is how we know - when they fire FUD at us “ oh SAVA cherry picks their patients.. “ no SAVA goes one above ALL other companies with a spinal tap actually shorty to KNOW patients DO have Alzheimer’s 🖕🏻” 😂😂
  • N
    Notthatkaren
    The interview, while compelling, didn't help the SP at all. Lots of low/no revenue companies down today, so not too concerned. Play the waiting game....
  • A
    Anthony
    Great interview with Dr. Nikolov. He refuted every single point in that BS report by QCM. Really exposed it for the hit piece it was.
  • J
    JOHN
    Great interview with Joe Springer Dr. Nickolov.......thats 3 great interviews now, this one with Dr. Nickolov is a must see,lots of Q&A, it really confirms what all us Longs were hoping for......confirmation by first hand knowledge...."The Horses Mouth" PS...The Dr. said he does NOT own any shares
  • H
    Hen
    Why is there no pre-market trade?
  • p
    pueo
    in 2019, my investment in sava was made with the expectation that phase2 and phase3 clinical trials and evaluations were still five years out. i have two more years remaining in my investment plan for sava. i view sava's science as a game changer with a winning strategy to mitigate alzheimer's disease with improved patient cognition, memory and behavior.

    in 2019, i was impressed with sava’s science enough to reinvest to support sava’s research. sava continued to validate my decision to increase my investment with phase2 clinical trial results that indicated improvements in patients’ cognition and memory as well as a decrease in biomarkers.

    my confidence in sava was bolstered by its securing a spa for both of its phase3 clinical trials, opening 91 clinical trial sites, of which 43 are now actively recruiting and dosing patients.

    the fact that sava secured the spa, opened clinical trial sites and began dosing patients further validated my confidence in sava as this was accomplished while an objectively baseless citizen's petition was submitted to the fda in an attempt to interfere with and stop sava's application for market approval of simufilam as well as any clinical trials.

    now that the cp has effectively been rejected by the fda, hearing from doctors involved in simufilam’s clinical testing and caretakers of alzheimer’s victims is even more encouraging to me as an investor and possible future alzheimer’s victim.

    phase3 participants are nearing the third month in clinical trials, results will not be immediately published, but, if the consistency in simufilam’s effects on alzheimer’s victims experienced in phase2 clinical trials continue through phase3 clinical trials, the results should be phenomenal.

    phenomenal for an investor and even more phenomenal for anyone who is or may become an alzheimer’s victim.

    besides the upcoming three and six month milestones for phase3 clinical trials, an important date for investors is july.22.2022, when pfizer’s agreement with eisai, a japanese alzheimer’s disease research and developement company, expires. pfizer may be interested in sava’s science and progress enough to switch their interest to sava.
  • B
    BRIAN
    Some Phase III participants are in nearly 3 months. Rumors of Simufilam's effectiveness are bound to leak.
  • R
    Rafael
    CP dismissal is coming. Expecting it at any moment now, will be before Feb deadline IMO. Clock’s ticking
  • B
    Bob
    Everyone do yourself a big favor and watch Joe Springer interview Dr Nikola. JT used CP to tank stock to enrich Bredt and Pitt and smear Sava. But his main goal is SEC Whistleblower angle which he wrote and has an advantage. But Dr Nikola confirmed he was contacted by sec and eagerly shared docs which will clear Sava imo. As Dr Burns said shorts “days are numbered”. CP will be dismissed and Sec will exonerate Sava while DOJ indicts JT , Bredt , Pitt and the short cabal with short and distort
  • J
    JR
    The Joe Springer interview of the researchers should stop. The reason is that the researchers can not divulge anything about the study that compromises it. The P3 is placebo controlled blinded study. We don’t want that compromised in any way. We should wait for the data.
  • k
    kman
    WOW, up to over 53% cost to borrow. MMs planning for huge SP increase.
  • Y
    YETI
    NASDAQ:SAVA) have earned a consensus recommendation of "Buy" from the five brokerages that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $127.75.
  • N
    NIO’s Marco Polo Project
    Hold
  • K
    Kal
    I omitted my feeling about SAVA in my previous posts. I am a long time bull and remain very bullish. Thank you Remi and staff for what you developed. Everyone at Cassava Sciences are godsent.
  • p
    paul
    TWO interviews with Joe Springer confirmed for THURSDAY one at 10 am & one at 2 pm with a doctors who ran the phase 2 trials and now started phase 3! Wow this is going to be two great ones! Don’t miss these longs.. Thursday is going to be GREAT! Joe fighting the hood fight for SAVA & longs! Hold your shares! 👍